Anterior Advantage With KINCISE

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-28

Study Completion Date

2022-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a post-market prospective, 1:1 randomized, multicenter non-inferiority study to compare the femoral broaching time for THA with the Anterior Advantage approach with KINCISE vs. without KINCISE. Follow-up will continue through 24 weeks post-op.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gait Initiation and Transition From Double to Single Support in Patients With Unilateral Primary Coxarthrosis

NCT06258369

Primary; Coxarthrosis

RECRUITING NA

KINCISE™ Surgical Automated System in Total Hip Arthroplasty (THA)

NCT05223777

Osteoarthritis, Hip

UNKNOWN NA

Cup Position in THA With Standard Instruments

NCT03189303

Osteoarthritis; Rheumatoid Arthritis; Post Traumatic Arthritis

COMPLETED

Efficiency and Safety of Navigation Aids in Total Hip Arthroplasty With Direct Anterior Approach

NCT07134036

Osteoarthritis, Hip Femur Head Necrosis Developmental Dysplasia of the Hip

COMPLETED NA

Comparison Between Automated and Manual Component Impaction in Total Hip Arthroplasty

NCT05480813

Total Hip Arthroplasty (THA)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary endpoint is femoral broaching time (in minutes), which is collected intraoperatively. The primary objective is to demonstrate that femoral broaching time with KINCISE is non-inferior to femoral broaching time with manual instruments (not using KINCISE) when used in THA with Anterior Advantage.

Note: If non-inferiority is successfully demonstrated, then the study will be deemed to be successful, and a test for superiority of femoral broaching time will be conducted.

If the primary endpoint analysis successfully demonstrates non-inferiority of femoral broaching time, then the following three secondary objectives will be assessed with formal hypotheses, in order, under a gatekeeping strategy:

* Non-inferiority of skin-to-skin OR time when KINCISE is used vs. when KINCISE is not used.
* Non-inferiority of the percent of subjects with optimal acetabular cup abduction angle when KINCISE is used vs. when KINCISE is not used.
* Non-inferiority of the percent of subjects with optimal acetabular cup version angle when KINCISE is used vs. when KINCISE is not used.

In addition, the following secondary endpoints do not have prospectively planned hypotheses; these will be summarized for both treatment groups:

* Harris Hip Score (HHS) and HHS change from preoperative baseline
* Forgotten Joint Score (FJS) and FJS change from 6-week postoperative baseline
* EQ-5D-5L and changes in these assessments from preoperative baseline
* Pain (Groin, Thigh, and Buttock)
* Patient Satisfaction
* Post-op time when functional activities can be accomplished (return to work, self-care, etc.)
* Radiographic Outcomes (based upon AP Hip, AP Pelvis, and Lateral)
* Length of hospital stay after index THA
* Re-hospitalizations during the study (including a specific summary of re-hospitalizations within 90 days)
* Narcotic drug usage throughout the study (participant reported)
* Complications (including a specific summary of complications within 90 days post-surgery)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis Rheumatoid Arthritis Post Traumatic Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1:1 Block Randomization

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anterior Approach with KINCISE

Anterior Approach THA using KINCISE(TM) Surgical Automated System

Group Type EXPERIMENTAL

KINCISE(TM) Surgical Automated System

Intervention Type DEVICE

Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System

Anterior Approach without KINCISE

Anterior Approach THA with a mallet (without KINCISE)

Group Type ACTIVE_COMPARATOR

KINCISE(TM) Surgical Automated System

Intervention Type DEVICE

Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KINCISE(TM) Surgical Automated System

Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient is undergoing a standard of care primary cementless hip replacement with the Pinnacle cup and a Corail or Actis stem via the Anterior Advantage approach. All devices are to be used according to the approved indications.
2. Individuals who are able to speak, read, and comprehend the Institutional Review Board approved Informed Consent Document and willing and able to provide informed patient consent for participation in the study and have authorized the transfer of his/her information to DePuy Synthes.
3. Individuals who are willing and able to complete follow-up visits and questionnaires as specified by the study protocol.
4. Individuals who are not bedridden per the discretion of the investigator (The intent of "not bedridden" means a permanent situation, not a temporary situation as in a hip fracture or trauma case).
5. Individuals who are a minimum age of 21 years at the time of consent.

Exclusion Criteria

1. Active local or systemic infection.
2. Loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb rendering the procedure unjustified.
3. Poor bone quality, such as osteoporosis, where, in the surgeon's opinion, there could be considerable migration of the prosthesis or a significant chance of fracture of the femoral shaft and/or the lack of adequate bone to support the implant(s).
4. Charcot's or Paget's disease.
5. The Subject is a woman who is pregnant or lactating.
6. Subject had a contralateral amputation.
7. Previous partial hip replacement in affected hip.
8. Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three months.
9. Contralateral hip was replaced less than 3 months prior to surgery date, contralateral hip is already enrolled in the study, or simultaneous or staged hip replacement is planned
10. Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
11. Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.
12. Subject has a medical condition with less than 2 years of life expectancy.
13. Subject, in the opinion of the Investigator, is a drug or alcohol abuser or has a physical or psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No